AI Earnings Predictions for Medtronic plc. (MDT)

mdt-202602170001613103H91 VY19false00016131032026-02-172026-02-170001613103mdt:A1.125SeniorNotesDue2027Member2026-02-172026-02-170001613103mdt:A0.375SeniorNotesDue2028Member2026-02-172026-02-170001613103mdt:A3.000SeniorNotesDue2028Member2026-02-172026-02-170001613103mdt:A3.650SeniorNotesDue2029Member2026-02-172026-02-170001613103mdt:A2.950SeniorNotesDue2030Member2026-02-172026-02-170001613103mdt:A1.625SeniorNotesDue2031Member2026-02-172026-02-170001613103mdt:A1.000SeniorNotesDue2031Member2026-02-172026-02-170001613103mdt:A3.125SeniorNotesDue2031Member2026-02-172026-02-170001613103mdt:A0.750SeniorNotesDue2032Member2026-02-172026-02-170001613103mdt:A3.375SeniorNotesDue2034Member2026-02-172026-02-170001613103mdt:A3.875SeniorNotesDue2036Member2026-02-172026-02-170001613103mdt:A2.250SeniorNotesDue2039Member2026-02-172026-02-170001613103mdt:A1.500SeniorNotesDue2039Member2026-02-172026-02-170001613103mdt:A1.375SeniorNotesDue2040Member2026-02-172026-02-170001613103mdt:A4.150SeniorNotesDue2043Member2026-02-172026-02-170001613103mdt:A4.200SeniorNotesDue2045Member2026-02-172026-02-170001613103mdt:A1.750SeniorNotesDue2049Member2026-02-172026-02-170001613103mdt:A1.625SeniorNotesDue2050Member2026-02-172026-02-170001613103mdt:A4.150SeniorNotesDue2053Member2026-02-172026-02-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

Building Two Parkmore Business Park West Galway, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 3.650% Senior Notes due 2029MDT/29New York Stock Exchange 2.950% Senior Notes due 2030MDT/30New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 3.875% Senior Notes due 2036MDT/36New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 4.150% Senior Notes due 2043MDT/43ANew York Stock Exchange 4.200% Senior Notes due 2045MDT/45New York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange 4.150% Senior Notes due 2053MDT/53New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On February 17, 2026, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its third quarter fiscal year 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.Exhibits.

(d) List of Exhibits Exhibit Number  Description

99.1 Press release of Medtronic plc, dated February 17, 2026

104Cover Page Interactive Data File (embedded with th

mdt-202511180001613103H91 VY19false00016131032025-11-182025-11-180001613103mdt:A1.125SeniorNotesDue2027Member2025-11-182025-11-180001613103mdt:A0.375SeniorNotesDue2028Member2025-11-182025-11-180001613103mdt:A3.000SeniorNotesDue2028Member2025-11-182025-11-180001613103mdt:A3.650SeniorNotesDue2029Member2025-11-182025-11-180001613103mdt:A2.950SeniorNotesDue2030Member2025-11-182025-11-180001613103mdt:A1.625SeniorNotesDue2031Member2025-11-182025-11-180001613103mdt:A1.000SeniorNotesDue2031Member2025-11-182025-11-180001613103mdt:A3.125SeniorNotesDue2031Member2025-11-182025-11-180001613103mdt:A0.750SeniorNotesDue2032Member2025-11-182025-11-180001613103mdt:A3.375SeniorNotesDue2034Member2025-11-182025-11-180001613103mdt:A3.875SeniorNotesDue2036Member2025-11-182025-11-180001613103mdt:A2.250SeniorNotesDue2039Member2025-11-182025-11-180001613103mdt:A1.500SeniorNotesDue2039Member2025-11-182025-11-180001613103mdt:A1.375SeniorNotesDue2040Member2025-11-182025-11-180001613103mdt:A4.150SeniorNotesDue2043Member2025-11-182025-11-180001613103mdt:A4.200SeniorNotesDue2045Member2025-11-182025-11-180001613103mdt:A1.750SeniorNotesDue2049Member2025-11-182025-11-180001613103mdt:A1.625SeniorNotesDue2050Member2025-11-182025-11-180001613103mdt:A4.150SeniorNotesDue2053Member2025-11-182025-11-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

Building Two Parkmore Business Park West Galway, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 3.650% Senior Notes due 2029MDT/29New York Stock Exchange 2.950% Senior Notes due 2030MDT/30New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 3.875% Senior Notes due 2036MDT/36New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 4.150% Senior Notes due 2043MDT/43ANew York Stock Exchange 4.200% Senior Notes due 2045MDT/45New York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange 4.150% Senior Notes due 2053MDT/53New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On November 18, 2025, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its second quarter fiscal year 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.Exhibits.

(d) List of Exhibits Exhibit Number  Description

99.1 Press release of Medtronic plc, dated November 18, 2025

104Cover Page Interactive Data File (embedded with t

mdt-202508180001613103H91 VY19false00016131032025-08-182025-08-180001613103us-gaap:CommonStockMember2025-08-182025-08-180001613103mdt:A0.000SeniorNotesDue2025Member2025-08-182025-08-180001613103mdt:A2.625SeniorNotesDue2025Member2025-08-182025-08-180001613103mdt:A1.125SeniorNotesDue2027Member2025-08-182025-08-180001613103mdt:A0.375SeniorNotesDue2028Member2025-08-182025-08-180001613103mdt:A3.000SeniorNotesDue2028Member2025-08-182025-08-180001613103mdt:A3.650SeniorNotesDue2029Member2025-08-182025-08-180001613103mdt:A1.625SeniorNotesDue2031Member2025-08-182025-08-180001613103mdt:A1.000SeniorNotesDue2031Member2025-08-182025-08-180001613103mdt:A3.125SeniorNotesDue2031Member2025-08-182025-08-180001613103mdt:A0.750SeniorNotesDue2032Member2025-08-182025-08-180001613103mdt:A3.375SeniorNotesDue2034Member2025-08-182025-08-180001613103mdt:A3.875SeniorNotesDue2036Member2025-08-182025-08-180001613103mdt:A2.250SeniorNotesDue2039Member2025-08-182025-08-180001613103mdt:A1.500SeniorNotesDue2039Member2025-08-182025-08-180001613103mdt:A1.375SeniorNotesDue2040Member2025-08-182025-08-180001613103mdt:A4.150SeniorNotesDue2043Member2025-08-182025-08-180001613103mdt:A1.750SeniorNotesDue2049Member2025-08-182025-08-180001613103mdt:A1.625SeniorNotesDue2050Member2025-08-182025-08-180001613103mdt:A4.150SeniorNotesDue2053Member2025-08-182025-08-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2025

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

Building Two Parkmore Business Park West Galway, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 3.650% Senior Notes due 2029MDT/29New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 3.875% Senior Notes due 2036MDT/36New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 4.150% Senior Notes due 2043MDT/43ANew York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange 4.150% Senior Notes due 2053MDT/53New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On August 19, 2025, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its first quarter fiscal year 2026 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangemen

mdt-202505210001613103Medtronic plcH91 VY19false00016131032025-05-212025-05-210001613103us-gaap:CommonStockMember2025-05-212025-05-210001613103mdt:SeniorNotes2019Due2025Member2025-05-212025-05-210001613103mdt:SeniorNotes2020Due2025Member2025-05-212025-05-210001613103mdt:SeniorNotesDue2025Member2025-05-212025-05-210001613103mdt:SeniorNotes2019Due2027Member2025-05-212025-05-210001613103mdt:SeniorNotes2020Due2028Member2025-05-212025-05-210001613103mdt:SeniorNotesDue2028Member2025-05-212025-05-210001613103mdt:SeniorNotes2019Due20311.625PercentMember2025-05-212025-05-210001613103mdt:SeniorNotes2019Due20311.00PercentMember2025-05-212025-05-210001613103mdt:SeniorNotesDue2031Member2025-05-212025-05-210001613103mdt:SeniorNotes2020Due2032Member2025-05-212025-05-210001613103mdt:SeniorNotesDue2034Member2025-05-212025-05-210001613103mdt:SeniorNotes2019Due20392.250PercentMember2025-05-212025-05-210001613103mdt:SeniorNotes2019Due20391.50PercentMember2025-05-212025-05-210001613103mdt:SeniorNotes2020Due2040Member2025-05-212025-05-210001613103mdt:SeniorNotes2019Due2049Member2025-05-212025-05-210001613103mdt:SeniorNotes2020Due2050Member2025-05-212025-05-210001613103mdt:A4.150SeniorNotesDue2043Member2025-05-212025-05-210001613103mdt:A1.750SeniorNotesDue2049Member2025-05-212025-05-210001613103mdt:A1.625SeniorNotesDue2050Member2025-05-212025-05-210001613103mdt:A4.150SeniorNotesDue2053Member2025-05-212025-05-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

Building Two Parkmore Business Park West Galway, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.250% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 3.650% Senior Notes due 2029MDT/29New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 3.875% Senior Notes due 2036MDT/36New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 4.150% Senior Notes due 2043MDT/43ANew York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange 4.150% Senior Notes due 2053MDT/53New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On May 21, 2025, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its full year and fourth quarter fiscal year 2025 financial results. A copy of the Medtronic financial results press release is furnis

mdt-202502180001613103H91 VY19false00016131032025-02-182025-02-180001613103us-gaap:CommonStockMember2025-02-182025-02-180001613103mdt:A0.250SeniorNotesDue2025Member2025-02-182025-02-180001613103mdt:A0.000SeniorNotesDue2025Member2025-02-182025-02-180001613103mdt:A2.625SeniorNotesDue2025Member2025-02-182025-02-180001613103mdt:A1.125SeniorNotesDue2027Member2025-02-182025-02-180001613103mdt:A0.375SeniorNotesDue2028Member2025-02-182025-02-180001613103mdt:A3.000SeniorNotesDue2028Member2025-02-182025-02-180001613103mdt:A3.650SeniorNotesDue2029Member2025-02-182025-02-180001613103mdt:A1.625SeniorNotesDue2031Member2025-02-182025-02-180001613103mdt:A1.000SeniorNotesDue2031Member2025-02-182025-02-180001613103mdt:A3.125SeniorNotesDue2031Member2025-02-182025-02-180001613103mdt:A0.750SeniorNotesDue2032Member2025-02-182025-02-180001613103mdt:A3.375SeniorNotesDue2034Member2025-02-182025-02-180001613103mdt:A3.875SeniorNotesDue2036Member2025-02-182025-02-180001613103mdt:A2.250SeniorNotesDue2039Member2025-02-182025-02-180001613103mdt:A1.500SeniorNotesDue2039Member2025-02-182025-02-180001613103mdt:A1.375SeniorNotesDue2040Member2025-02-182025-02-180001613103mdt:A4.150SeniorNotesDue2043Member2025-02-182025-02-180001613103mdt:A1.750SeniorNotesDue2049Member2025-02-182025-02-180001613103mdt:A1.625SeniorNotesDue2050Member2025-02-182025-02-180001613103mdt:A4.150SeniorNotesDue2053Member2025-02-182025-02-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

Building Two Parkmore Business Park West Galway, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.250% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 3.650% Senior Notes due 2029MDT/29New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 3.875% Senior Notes due 2036MDT/36New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 4.150% Senior Notes due 2043MDT/43ANew York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange 4.150% Senior Notes due 2053MDT/53New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On February 18, 2025, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its third quarter fiscal year 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.

mdt-202411190001613103H91 VY19false00016131032024-11-192024-11-190001613103us-gaap:CommonStockMember2024-11-192024-11-190001613103mdt:A0.250SeniorNotesDue2025Member2024-11-192024-11-190001613103mdt:A0.000SeniorNotesDue2025Member2024-11-192024-11-190001613103mdt:A2.625SeniorNotesDue2025Member2024-11-192024-11-190001613103mdt:A1.125SeniorNotesDue2027Member2024-11-192024-11-190001613103mdt:A0.375SeniorNotesDue2028Member2024-11-192024-11-190001613103mdt:A3.000SeniorNotesDue2028Member2024-11-192024-11-190001613103mdt:A3.650SeniorNotesDue2029Member2024-11-192024-11-190001613103mdt:A1.625SeniorNotesDue2031Member2024-11-192024-11-190001613103mdt:A1.000SeniorNotesDue2031Member2024-11-192024-11-190001613103mdt:A3.125SeniorNotesDue2031Member2024-11-192024-11-190001613103mdt:A0.750SeniorNotesDue2032Member2024-11-192024-11-190001613103mdt:A3.375SeniorNotesDue2034Member2024-11-192024-11-190001613103mdt:A3.875SeniorNotesDue2036Member2024-11-192024-11-190001613103mdt:A2.250SeniorNotesDue2039Member2024-11-192024-11-190001613103mdt:A1.500SeniorNotesDue2039Member2024-11-192024-11-190001613103mdt:A1.375SeniorNotesDue2040Member2024-11-192024-11-190001613103mdt:A4.150SeniorNotesDue2043Member2024-11-192024-11-190001613103mdt:A1.750SeniorNotesDue2049Member2024-11-192024-11-190001613103mdt:A1.625SeniorNotesDue2050Member2024-11-192024-11-190001613103mdt:A4.150SeniorNotesDue2053Member2024-11-192024-11-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2024

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

Building Two Parkmore Business Park West Galway, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.250% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 3.650% Senior Notes due 2029MDT/29New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 3.875% Senior Notes due 2036MDT/36New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 4.150% Senior Notes due 2043MDT/43ANew York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange 4.150% Senior Notes due 2053MDT/53New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On November 19, 2024, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its second quarter fiscal year 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9

mdt-202408200001613103H91 VY19false00016131032024-08-202024-08-200001613103us-gaap:CommonStockMember2024-08-202024-08-200001613103mdt:A0.250SeniorNotesDue2025Member2024-08-202024-08-200001613103mdt:A0.000SeniorNotesDue2025Member2024-08-202024-08-200001613103mdt:A2.625SeniorNotesDue2025Member2024-08-202024-08-200001613103mdt:A1.125SeniorNotesDue2027Member2024-08-202024-08-200001613103mdt:A0.375SeniorNotesDue2028Member2024-08-202024-08-200001613103mdt:A3.000SeniorNotesDue2028Member2024-08-202024-08-200001613103mdt:A3.650SeniorNotesDue2029Member2024-08-202024-08-200001613103mdt:A1.625SeniorNotesDue2031Member2024-08-202024-08-200001613103mdt:A1.000SeniorNotesDue2031Member2024-08-202024-08-200001613103mdt:A3.125SeniorNotesDue2031Member2024-08-202024-08-200001613103mdt:A0.750SeniorNotesDue2032Member2024-08-202024-08-200001613103mdt:A3.375SeniorNotesDue2034Member2024-08-202024-08-200001613103mdt:A3.875SeniorNotesDue2036Member2024-08-202024-08-200001613103mdt:A2.250SeniorNotesDue2039Member2024-08-202024-08-200001613103mdt:A1.500SeniorNotesDue2039Member2024-08-202024-08-200001613103mdt:A1.375SeniorNotesDue2040Member2024-08-202024-08-200001613103mdt:A4.150SeniorNotesDue2043Member2024-08-202024-08-200001613103mdt:A1.750SeniorNotesDue2049Member2024-08-202024-08-200001613103mdt:A1.625SeniorNotesDue2050Member2024-08-202024-08-200001613103mdt:A4.150SeniorNotesDue2053Member2024-08-202024-08-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

Building Two Parkmore Business Park West Galway, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.250% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 3.650% Senior Notes due 2029MDT/29New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 3.875% Senior Notes due 2036MDT/36New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 4.150% Senior Notes due 2043MDT/43ANew York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange 4.150% Senior Notes due 2053MDT/53New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On August 20, 2024, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its first quarter fiscal year 2025 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.E

mdt-202405230001613103Medtronic plcD02 XH02false00016131032024-05-232024-05-230001613103us-gaap:CommonStockMember2024-05-232024-05-230001613103mdt:SeniorNotes2019Due2025Member2024-05-232024-05-230001613103mdt:SeniorNotes2020Due2025Member2024-05-232024-05-230001613103mdt:SeniorNotesDue2025Member2024-05-232024-05-230001613103mdt:SeniorNotes2019Due2027Member2024-05-232024-05-230001613103mdt:SeniorNotes2020Due2028Member2024-05-232024-05-230001613103mdt:SeniorNotesDue2028Member2024-05-232024-05-230001613103mdt:SeniorNotes2019Due20311.625PercentMember2024-05-232024-05-230001613103mdt:SeniorNotes2019Due20311.00PercentMember2024-05-232024-05-230001613103mdt:SeniorNotesDue2031Member2024-05-232024-05-230001613103mdt:SeniorNotes2020Due2032Member2024-05-232024-05-230001613103mdt:SeniorNotesDue2034Member2024-05-232024-05-230001613103mdt:SeniorNotes2019Due20392.250PercentMember2024-05-232024-05-230001613103mdt:SeniorNotes2019Due20391.50PercentMember2024-05-232024-05-230001613103mdt:SeniorNotes2020Due2040Member2024-05-232024-05-230001613103mdt:SeniorNotes2019Due2049Member2024-05-232024-05-230001613103mdt:SeniorNotes2020Due2050Member2024-05-232024-05-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.250% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On May 23, 2024, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its full year and fourth quarter fiscal year 2024 financial results. A copy of the Medtronic financial results press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01.Exhibits

(d) List of Exhibits Exhibit Number  Description

99.1 Press release of Medtronic plc, dated May 23, 2024

104Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medtronic plc

By /s/ Karen L. Parkhi

mdt-202402130001613103D02 XH02false00016131032024-02-132024-02-130001613103us-gaap:CommonStockMember2024-02-132024-02-130001613103mdt:SeniorNotes2019Due2025Member2024-02-132024-02-130001613103mdt:SeniorNotes2020Due2025Member2024-02-132024-02-130001613103mdt:SeniorNotes2022Due2025Member2024-02-132024-02-130001613103mdt:SeniorNotes2019Due2027Member2024-02-132024-02-130001613103mdt:SeniorNotes2020Due2028Member2024-02-132024-02-130001613103mdt:SeniorNotes2022Due2028Member2024-02-132024-02-130001613103mdt:SeniorNotes2019Due20311.625PercentMember2024-02-132024-02-130001613103mdt:SeniorNotes2019Due20311.00PercentMember2024-02-132024-02-130001613103mdt:SeniorNotes2022Due2031Member2024-02-132024-02-130001613103mdt:SeniorNotes2020Due2032Member2024-02-132024-02-130001613103mdt:SeniorNotes2022Due2034Member2024-02-132024-02-130001613103mdt:SeniorNotes2019Due20392.250PercentMember2024-02-132024-02-130001613103mdt:SeniorNotes2019Due20391.50PercentMember2024-02-132024-02-130001613103mdt:SeniorNotes2020Due2040Member2024-02-132024-02-130001613103mdt:SeniorNotes2019Due2049Member2024-02-132024-02-130001613103mdt:SeniorNotes2020Due2050Member2024-02-132024-02-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.250% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On February 20, 2024, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its third quarter fiscal year 2024 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As referenced in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K, the Company announced on February 20, 2024 its decision to wind down and exit the ventilator business and combine the remaining businesses within its Patient Monitoring and Respiratory Interventions operating units into a single opera

mdt-202311210001613103D02 XH02false00016131032023-11-212023-11-210001613103us-gaap:CommonStockMember2023-11-212023-11-210001613103mdt:SeniorNotes2019Due2025Member2023-11-212023-11-210001613103mdt:SeniorNotes2020Due2025Member2023-11-212023-11-210001613103mdt:SeniorNotes2022Due2025Member2023-11-212023-11-210001613103mdt:SeniorNotes2019Due2027Member2023-11-212023-11-210001613103mdt:SeniorNotes2020Due2028Member2023-11-212023-11-210001613103mdt:SeniorNotes2022Due2028Member2023-11-212023-11-210001613103mdt:SeniorNotes2019Due20311.625PercentMember2023-11-212023-11-210001613103mdt:SeniorNotes2019Due20311.00PercentMember2023-11-212023-11-210001613103mdt:SeniorNotes2022Due2031Member2023-11-212023-11-210001613103mdt:SeniorNotes2020Due2032Member2023-11-212023-11-210001613103mdt:SeniorNotes2022Due2034Member2023-11-212023-11-210001613103mdt:SeniorNotes2019Due20392.250PercentMember2023-11-212023-11-210001613103mdt:SeniorNotes2019Due20391.50PercentMember2023-11-212023-11-210001613103mdt:SeniorNotes2020Due2040Member2023-11-212023-11-210001613103mdt:SeniorNotes2019Due2049Member2023-11-212023-11-210001613103mdt:SeniorNotes2020Due2050Member2023-11-212023-11-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.250% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On November 21, 2023, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its second quarter fiscal year 2024 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.      Exhibits.

(d) List of Exhibits Exhibit Number  Description

99.1 Press release of Medtronic plc, dated November 21, 2023

104Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medtronic plc

By /s/ Karen L. Parkhill Date: November 21, 2023   Karen L.

mdt-202308220001613103D02 XH02false00016131032023-08-222023-08-220001613103us-gaap:CommonStockMember2023-08-222023-08-220001613103mdt:SeniorNotes2019Due2025Member2023-08-222023-08-220001613103mdt:SeniorNotes2020Due2025Member2023-08-222023-08-220001613103mdt:SeniorNotes2022Due2025Member2023-08-222023-08-220001613103mdt:SeniorNotes2019Due2027Member2023-08-222023-08-220001613103mdt:SeniorNotes2020Due2028Member2023-08-222023-08-220001613103mdt:SeniorNotes2022Due2028Member2023-08-222023-08-220001613103mdt:SeniorNotes2019Due20311.625PercentMember2023-08-222023-08-220001613103mdt:SeniorNotes2019Due20311.00PercentMember2023-08-222023-08-220001613103mdt:SeniorNotes2022Due2031Member2023-08-222023-08-220001613103mdt:SeniorNotes2020Due2032Member2023-08-222023-08-220001613103mdt:SeniorNotes2022Due2034Member2023-08-222023-08-220001613103mdt:SeniorNotes2019Due20392.250PercentMember2023-08-222023-08-220001613103mdt:SeniorNotes2019Due20391.50PercentMember2023-08-222023-08-220001613103mdt:SeniorNotes2020Due2040Member2023-08-222023-08-220001613103mdt:SeniorNotes2019Due2049Member2023-08-222023-08-220001613103mdt:SeniorNotes2020Due2050Member2023-08-222023-08-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 22, 2023

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.250% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On August 22, 2023, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its first quarter fiscal year 2024 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.      Exhibits.

(d) List of Exhibits Exhibit Number  Description

99.1 Press release of Medtronic plc, dated August 22, 2023

104Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medtronic plc

By /s/ Karen L. Parkhill Date: August 22, 2023   Karen L. Parkhill

mdt-202305250001613103Medtronic plcD02 XH02false00016131032023-05-252023-05-250001613103us-gaap:CommonStockMember2023-05-252023-05-250001613103mdt:SeniorNotes2019Due2025Member2023-05-252023-05-250001613103mdt:SeniorNotes2020Due2025Member2023-05-252023-05-250001613103mdt:SeniorNotesDue2025Member2023-05-252023-05-250001613103mdt:SeniorNotes2019Due2027Member2023-05-252023-05-250001613103mdt:SeniorNotes2020Due2028Member2023-05-252023-05-250001613103mdt:SeniorNotesDue2028Member2023-05-252023-05-250001613103mdt:SeniorNotes2019Due20311.625PercentMember2023-05-252023-05-250001613103mdt:SeniorNotes2019Due20311.00PercentMember2023-05-252023-05-250001613103mdt:SeniorNotesDue2031Member2023-05-252023-05-250001613103mdt:SeniorNotes2020Due2032Member2023-05-252023-05-250001613103mdt:SeniorNotesDue2034Member2023-05-252023-05-250001613103mdt:SeniorNotes2019Due20392.250PercentMember2023-05-252023-05-250001613103mdt:SeniorNotes2019Due20391.50PercentMember2023-05-252023-05-250001613103mdt:SeniorNotes2020Due2040Member2023-05-252023-05-250001613103mdt:SeniorNotes2019Due2049Member2023-05-252023-05-250001613103mdt:SeniorNotes2020Due2050Member2023-05-252023-05-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.250% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.000% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.500% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.750% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On May 25, 2023, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its full year and fourth quarter fiscal year 2023 financial results. A copy of the Medtronic financial results press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01.      Exhibits.

(d) List of Exhibits Exhibit Number  Description

99.1 Press release of Medtronic plc, dated May 25, 2023

104Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medtronic plc

By /s/ Karen L.

mdt-202302210001613103Medtronic plcD02 XH02false00016131032023-02-212023-02-210001613103us-gaap:CommonStockMember2023-02-212023-02-210001613103mdt:SeniorNotes2019Due20230.375PercentMember2023-02-212023-02-210001613103mdt:SeniorNotes2020Due2023Member2023-02-212023-02-210001613103mdt:SeniorNotes2019Due2025Member2023-02-212023-02-210001613103mdt:SeniorNotes2020Due2025Member2023-02-212023-02-210001613103mdt:SeniorNotes2022Due2025Member2023-02-212023-02-210001613103mdt:SeniorNotes2019Due2027Member2023-02-212023-02-210001613103mdt:SeniorNotes2020Due2028Member2023-02-212023-02-210001613103mdt:SeniorNotes2022Due2028Member2023-02-212023-02-210001613103mdt:SeniorNotes2019Due20311.625PercentMember2023-02-212023-02-210001613103mdt:SeniorNotes2019Due20311.00PercentMember2023-02-212023-02-210001613103mdt:SeniorNotes2022Due2031Member2023-02-212023-02-210001613103mdt:SeniorNotes2020Due2032Member2023-02-212023-02-210001613103mdt:SeniorNotes2022Due2034Member2023-02-212023-02-210001613103mdt:SeniorNotes2019Due20392.250PercentMember2023-02-212023-02-210001613103mdt:SeniorNotes2019Due20391.50PercentMember2023-02-212023-02-210001613103mdt:SeniorNotes2020Due2040Member2023-02-212023-02-210001613103mdt:SeniorNotes2019Due2049Member2023-02-212023-02-210001613103mdt:SeniorNotes2020Due2050Member2023-02-212023-02-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.375% Senior Notes due 2023MDT/23BNew York Stock Exchange 0.000% Senior Notes due 2023MDT/23CNew York Stock Exchange 0.25% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.625% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.00% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.50% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.75% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On February 21, 2023, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its third quarter fiscal year 2023 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.      Exhibits.

(d) List of Exhibits Exhibit Number  Description

99.1 Press release of Medtronic plc, dated February 21, 2023

104Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATUR

mdt-202211220001613103Medtronic plcD02 XH02false00016131032022-11-222022-11-220001613103us-gaap:CommonStockMember2022-11-222022-11-220001613103mdt:SeniorNotes2019Due2022Member2022-11-222022-11-220001613103mdt:SeniorNotes2019Due20230.375PercentMember2022-11-222022-11-220001613103mdt:SeniorNotes2020Due2023Member2022-11-222022-11-220001613103mdt:SeniorNotes2019Due2025Member2022-11-222022-11-220001613103mdt:SeniorNotes2020Due2025Member2022-11-222022-11-220001613103mdt:SeniorNotes2022Due2025Member2022-11-222022-11-220001613103mdt:SeniorNotes2019Due2027Member2022-11-222022-11-220001613103mdt:SeniorNotes2020Due2028Member2022-11-222022-11-220001613103mdt:SeniorNotes2022Due2028Member2022-11-222022-11-220001613103mdt:SeniorNotes2019Due20311.625PercentMember2022-11-222022-11-220001613103mdt:SeniorNotes2019Due20311.00PercentMember2022-11-222022-11-220001613103mdt:SeniorNotes2022Due2031Member2022-11-222022-11-220001613103mdt:SeniorNotes2020Due2032Member2022-11-222022-11-220001613103mdt:SeniorNotes2022Due2034Member2022-11-222022-11-220001613103mdt:SeniorNotes2019Due20392.250PercentMember2022-11-222022-11-220001613103mdt:SeniorNotes2019Due20391.50PercentMember2022-11-222022-11-220001613103mdt:SeniorNotes2020Due2040Member2022-11-222022-11-220001613103mdt:SeniorNotes2019Due2049Member2022-11-222022-11-220001613103mdt:SeniorNotes2020Due2050Member2022-11-222022-11-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.00% Senior Notes due 2022MDT/22BNew York Stock Exchange 0.375% Senior Notes due 2023MDT/23BNew York Stock Exchange 0.000% Senior Notes due 2023MDT/23CNew York Stock Exchange 0.25% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 2.650% Senior Notes due 2025MDT/25BNew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 3.000% Senior Notes due 2028MDT/28ANew York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.00% Senior Notes due 2031MDT/31ANew York Stock Exchange 3.125% Senior Notes due 2031MDT/31BNew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 3.375% Senior Notes due 2034MDT/34New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.50% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.75% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On November 22, 2022, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its second quarter fiscal year 2023 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.      Exhibits.

(d) List of Exhibits Exhibit Number  Description

99.1 Press release of Medtro

mdt-202208230001613103Medtronic plcD02 XH02false00016131032022-08-232022-08-230001613103us-gaap:CommonStockMember2022-08-232022-08-230001613103mdt:SeniorNotes2019Due2022Member2022-08-232022-08-230001613103mdt:SeniorNotes2019Due20230.375PercentMember2022-08-232022-08-230001613103mdt:SeniorNotes2020Due2023Member2022-08-232022-08-230001613103mdt:SeniorNotes2019Due2025Member2022-08-232022-08-230001613103mdt:SeniorNotes2020Due2025Member2022-08-232022-08-230001613103mdt:SeniorNotes2019Due2027Member2022-08-232022-08-230001613103mdt:SeniorNotes2020Due2028Member2022-08-232022-08-230001613103mdt:SeniorNotes2019Due20311.625PercentMember2022-08-232022-08-230001613103mdt:SeniorNotes2019Due20311.00PercentMember2022-08-232022-08-230001613103mdt:SeniorNotes2020Due2032Member2022-08-232022-08-230001613103mdt:SeniorNotes2019Due20392.250PercentMember2022-08-232022-08-230001613103mdt:SeniorNotes2019Due20391.50PercentMember2022-08-232022-08-230001613103mdt:SeniorNotes2020Due2040Member2022-08-232022-08-230001613103mdt:SeniorNotes2019Due2049Member2022-08-232022-08-230001613103mdt:SeniorNotes2020Due2050Member2022-08-232022-08-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.00% Senior Notes due 2022MDT/22BNew York Stock Exchange 0.375% Senior Notes due 2023MDT/23BNew York Stock Exchange 0.000% Senior Notes due 2023MDT/23CNew York Stock Exchange 0.25% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.00% Senior Notes due 2031MDT/31ANew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.50% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.75% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On August 23, 2022, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its first quarter fiscal year 2023 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.      Exhibits.

(d) List of Exhibits Exhibit Number  Description

99.1 Press release of Medtronic plc, dated August 23, 2022

104Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medtronic plc

By /s/ Karen L. Parkhill Date: August 23, 2022   Karen L. Parkhill Executive Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit Number  Description

9

mdt-202205260001613103Medtronic plcD02 XH02false00016131032022-05-262022-05-260001613103us-gaap:CommonStockMember2022-05-262022-05-260001613103mdt:SeniorNotes2019Due2022Member2022-05-262022-05-260001613103mdt:SeniorNotes2019Due20230.375PercentMember2022-05-262022-05-260001613103mdt:SeniorNotes2020Due2023Member2022-05-262022-05-260001613103mdt:SeniorNotes2019Due2025Member2022-05-262022-05-260001613103mdt:SeniorNotes2020Due2025Member2022-05-262022-05-260001613103mdt:SeniorNotes2019Due2027Member2022-05-262022-05-260001613103mdt:SeniorNotes2020Due2028Member2022-05-262022-05-260001613103mdt:SeniorNotes2019Due20311.625PercentMember2022-05-262022-05-260001613103mdt:SeniorNotes2019Due20311.00PercentMember2022-05-262022-05-260001613103mdt:SeniorNotes2020Due2032Member2022-05-262022-05-260001613103mdt:SeniorNotes2019Due20392.250PercentMember2022-05-262022-05-260001613103mdt:SeniorNotes2019Due20391.50PercentMember2022-05-262022-05-260001613103mdt:SeniorNotes2020Due2040Member2022-05-262022-05-260001613103mdt:SeniorNotes2019Due2049Member2022-05-262022-05-260001613103mdt:SeniorNotes2020Due2050Member2022-05-262022-05-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.00% Senior Notes due 2022MDT/22BNew York Stock Exchange 0.375% Senior Notes due 2023MDT/23BNew York Stock Exchange 0.000% Senior Notes due 2023MDT/23CNew York Stock Exchange 0.25% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.00% Senior Notes due 2031MDT/31ANew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.50% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.75% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On May 26, 2022, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its full year and fourth quarter fiscal year 2022 financial results. A copy of the Medtronic financial results press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01.Regulation FD Disclosure

On May 26, 2022, Medtronic plc (“Medtronic”) issued a joint press release with DaVita Inc. (“DaVita”) announcing the two companies’ intent to form a new, independent kidney care-focused medical device company (“NewCo”). A copy of the joint press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K. Medtronic is providing the following additional financial details related to the transaction. The transaction is not expected to have a material impact to Medtronic’s adjusted earni

mdt-202202220001613103Medtronic plcD02 XH02false00016131032022-02-222022-02-220001613103us-gaap:CommonStockMember2022-02-222022-02-220001613103mdt:SeniorNotes2019Due2022Member2022-02-222022-02-220001613103mdt:SeniorNotes2019Due20230.375PercentMember2022-02-222022-02-220001613103mdt:SeniorNotes2020Due2023Member2022-02-222022-02-220001613103mdt:SeniorNotes2019Due2025Member2022-02-222022-02-220001613103mdt:SeniorNotes2020Due2025Member2022-02-222022-02-220001613103mdt:SeniorNotes2019Due2027Member2022-02-222022-02-220001613103mdt:SeniorNotes2020Due2028Member2022-02-222022-02-220001613103mdt:SeniorNotes2019Due20311.625PercentMember2022-02-222022-02-220001613103mdt:SeniorNotes2019Due20311.00PercentMember2022-02-222022-02-220001613103mdt:SeniorNotes2020Due2032Member2022-02-222022-02-220001613103mdt:SeniorNotes2019Due20392.250PercentMember2022-02-222022-02-220001613103mdt:SeniorNotes2019Due20391.50PercentMember2022-02-222022-02-220001613103mdt:SeniorNotes2020Due2040Member2022-02-222022-02-220001613103mdt:SeniorNotes2019Due2049Member2022-02-222022-02-220001613103mdt:SeniorNotes2020Due2050Member2022-02-222022-02-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.00% Senior Notes due 2022MDT/22BNew York Stock Exchange 0.375% Senior Notes due 2023MDT/23BNew York Stock Exchange 0.000% Senior Notes due 2023MDT/23CNew York Stock Exchange 0.25% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.00% Senior Notes due 2031MDT/31ANew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.50% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.75% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On February 22, 2022, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its third quarter fiscal year 2022 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.      Exhibits.

(d) List of Exhibits Exhibit Number  Description

99.1 Press release of Medtronic plc, dated February 22, 2022

104Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medtronic plc

By /s/ Karen L. Parkhill Date: February 22, 2022   Karen L. Parkhill Executive Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit Number  Descri

mdt-202111230001613103Medtronic plcD02 XH02false00016131032021-11-232021-11-230001613103us-gaap:CommonStockMember2021-11-232021-11-230001613103mdt:SeniorNotes2019Due2022Member2021-11-232021-11-230001613103mdt:SeniorNotes2019Due20230.375PercentMember2021-11-232021-11-230001613103mdt:SeniorNotes2020Due2023Member2021-11-232021-11-230001613103mdt:SeniorNotes2019Due2025Member2021-11-232021-11-230001613103mdt:SeniorNotes2020Due2025Member2021-11-232021-11-230001613103mdt:SeniorNotes2019Due2027Member2021-11-232021-11-230001613103mdt:SeniorNotes2020Due2028Member2021-11-232021-11-230001613103mdt:SeniorNotes2019Due20311.625PercentMember2021-11-232021-11-230001613103mdt:SeniorNotes2019Due20311.00PercentMember2021-11-232021-11-230001613103mdt:SeniorNotes2020Due2032Member2021-11-232021-11-230001613103mdt:SeniorNotes2019Due20392.250PercentMember2021-11-232021-11-230001613103mdt:SeniorNotes2019Due20391.50PercentMember2021-11-232021-11-230001613103mdt:SeniorNotes2020Due2040Member2021-11-232021-11-230001613103mdt:SeniorNotes2019Due2049Member2021-11-232021-11-230001613103mdt:SeniorNotes2020Due2050Member2021-11-232021-11-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2021

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.00% Senior Notes due 2022MDT/22BNew York Stock Exchange 0.375% Senior Notes due 2023MDT/23BNew York Stock Exchange 0.000% Senior Notes due 2023MDT/23CNew York Stock Exchange 0.25% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.00% Senior Notes due 2031MDT/31ANew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.50% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.75% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On November 23, 2021, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its second quarter fiscal year 2022 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.      Exhibits.

(d) List of Exhibits Exhibit Number  Description

99.1 Press release of Medtronic plc, dated November 23, 2021

104Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Medtronic plc

By /s/ Karen L. Parkhill Date: November 23, 2021   Karen L. Parkhill Executive Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit Number  Descr

mdt-202108240001613103Medtronic plcD02 XH02false00016131032021-08-242021-08-240001613103us-gaap:CommonStockMember2021-08-242021-08-240001613103mdt:SeniorNotes2019Due2022Member2021-08-242021-08-240001613103mdt:SeniorNotes2019Due20230.375PercentMember2021-08-242021-08-240001613103mdt:SeniorNotes2020Due2023Member2021-08-242021-08-240001613103mdt:SeniorNotes2019Due2025Member2021-08-242021-08-240001613103mdt:SeniorNotes2020Due2025Member2021-08-242021-08-240001613103mdt:SeniorNotes2019Due2027Member2021-08-242021-08-240001613103mdt:SeniorNotes2020Due2028Member2021-08-242021-08-240001613103mdt:SeniorNotes2019Due20311.625PercentMember2021-08-242021-08-240001613103mdt:SeniorNotes2019Due20311.00PercentMember2021-08-242021-08-240001613103mdt:SeniorNotes2020Due2032Member2021-08-242021-08-240001613103mdt:SeniorNotes2019Due20392.250PercentMember2021-08-242021-08-240001613103mdt:SeniorNotes2019Due20391.50PercentMember2021-08-242021-08-240001613103mdt:SeniorNotes2020Due2040Member2021-08-242021-08-240001613103mdt:SeniorNotes2019Due2049Member2021-08-242021-08-240001613103mdt:SeniorNotes2019Due2049Member2021-02-232021-02-230001613103mdt:SeniorNotes2020Due2050Member2021-08-242021-08-24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2021

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.00% Senior Notes due 2022MDT/22BNew York Stock Exchange 0.375% Senior Notes due 2023MDT/23BNew York Stock Exchange 0.000% Senior Notes due 2023MDT/23CNew York Stock Exchange 0.25% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.00% Senior Notes due 2031MDT/31ANew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.50% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.75% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

On August 24, 2021, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its first quarter fiscal year 2022 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01.      Exhibits.

(d) List of Exhibits

Exhibit Number  Description

99.1 Press release of Medtronic plc, dated August 24, 2021

104Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDTRONIC PUBLIC LIMITED COMPANY

By /s/ Karen L. Parkhill Date: August 24, 2021   Karen L. Parkhill Executive Vice P

mdt-202105270001613103Medtronic plcD02 XH02false00016131032021-05-272021-05-270001613103us-gaap:CommonStockMember2021-05-272021-05-270001613103mdt:SeniorNotes2019Due2022Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due20230.375PercentMember2021-05-272021-05-270001613103mdt:SeniorNotes2020Due2023Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due2025Member2021-05-272021-05-270001613103mdt:SeniorNotes2020Due2025Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due2027Member2021-05-272021-05-270001613103mdt:A2020SeniorNotesDue2028Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due20311.625PercentMember2021-05-272021-05-270001613103mdt:SeniorNotes2019Due20311.00PercentMember2021-05-272021-05-270001613103mdt:A2020SeniorNotesDue2032Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due20392.250PercentMember2021-05-272021-05-270001613103mdt:SeniorNotes2019Due20391.50PercentMember2021-05-272021-05-270001613103mdt:SeniorNotes2020Due2040Member2021-05-272021-05-270001613103mdt:SeniorNotes2019Due2049Member2021-05-272021-05-270001613103mdt:SeniorNotes2020Due2050Member2021-05-272021-05-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2021

Medtronic plc (Exact name of Registrant as Specified in its Charter)

Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

20 On Hatch, Lower Hatch Street Dublin 2, Ireland (Address of principal executive offices) (Zip Code) +353 1 438-1700 (Registrant’s telephone number, including area code)

Not Applicable Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered Ordinary shares, par value $0.0001 per shareMDTNew York Stock Exchange 0.00% Senior Notes due 2022MDT/22BNew York Stock Exchange 0.375% Senior Notes due 2023MDT/23BNew York Stock Exchange 0.000% Senior Notes due 2023MDT/23CNew York Stock Exchange 0.25% Senior Notes due 2025MDT/25New York Stock Exchange 0.000% Senior Notes due 2025MDT/25ANew York Stock Exchange 1.125% Senior Notes due 2027MDT/27New York Stock Exchange 0.375% Senior Notes due 2028MDT/28New York Stock Exchange 1.625% Senior Notes due 2031MDT/31New York Stock Exchange 1.00% Senior Notes due 2031MDT/31ANew York Stock Exchange 0.750% Senior Notes due 2032MDT/32New York Stock Exchange 2.250% Senior Notes due 2039MDT/39ANew York Stock Exchange 1.50% Senior Notes due 2039MDT/39BNew York Stock Exchange 1.375% Senior Notes due 2040MDT/40ANew York Stock Exchange 1.75% Senior Notes due 2049MDT/49New York Stock Exchange 1.625% Senior Notes due 2050MDT/50New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02.Results of Operations and Financial Condition

Medtronic plc (the “Company”) is furnishing this Form 8-K/A to correct the “currency impact” line item in the GAAP to non-GAAP reconciliations attached to the earnings release issued by the Company on May 27, 2021 (the “Original Earnings Release”). The currency adjustment in the GAAP to non-GAAP reconciliations added amounts for currency impacts for certain items when such amounts should have been deducted. Currency impacts were accurately presented in all of the revenue tables attached to the Original Earnings Release and all financial metrics presented in the Original Earnings Release were correct other than the currency impact line item and corresponding currency impact adjusted measures in the GAAP to non-GAAP reconciliations attached to the Original Earnings Release. The Original Earnings Release and related financi